P & G Health Ltd

P&G Health Ltd. reported strong financial results for the 9-month fiscal year ending March 31, 2025, with sales reaching ₹918 crores, an 8% increase year-over-year compared to the comparable 9-month period. Profit after tax (PAT) saw a significant jump of 27%, totaling ₹234 crores. Over the past five years, the company has achieved consistent high single-digit sales growth and an average profit growth of 9%, alongside a 200 basis points expansion in net profit margin and a threefold increase in return on equity.

The company's robust performance is attributed to the successful execution of its Integrated Growth Strategy, built on five pillars: portfolio, superiority, productivity, constructive disruption, and an empowered organization. This strategy aims to grow markets, increase share, sales, consumer preference, and profit by continuously adapting to changing consumer and customer needs. Management emphasized that all five vectors of superiority—product, package, brand communication, retail execution, and value—work synergistically to deliver irresistible superiority to consumers and healthcare practitioners.

P&G Health is committed to delivering quality, trusted, and highly recommended superior products across its portfolio, including key brands like Neurobion, Livogen, Seven Seas, Evion, Polybion, and Nasivion. The company highlighted Neurobion's superior formulation, offering 3 times the strength of B vitamins for nerve health, and Evion's role in muscle health through its rich antioxidants. Recent brand communications, including an endorsement by Amitabh Bachchan for Neurobion, aim to enhance consumer awareness and symptom identification for timely treatment.

The company has transformed its go-to-market model, leveraging a strong super distributor network to enhance distribution, retail execution, and healthcare practitioner (HCP) engagement. This new model has significantly expanded coverage, with Neurobion's pharmacy reach increasing 1.4 times over the past five years, adding nearly 100,000 new stores. P&G Health is also actively working on initiatives to increase coverage in rural areas and broaden portfolio availability through e-commerce channels, partnering with platforms like 1MG, Pharmeasy, and Netmeds.

Productivity is a core component of the company's operating model, with P&G Health achieving over ₹40 crores in savings during the last fiscal year through various interventions. These savings are crucial for reinvesting in product superiority across all five vectors and staying ahead of consumer demands. The company's long-term focus on productivity has contributed to the 200 basis points net profit margin expansion over the past five years, demonstrating a strong 'productivity muscle'.

P&G Health has seen strong performance from its recent product launches and upgrades, which are contributing high single-digit growth to sales. Notable examples include Neurobion Alfa & Alfa D, which is experiencing high double-digit growth, and the upgraded Polybion Active with Mango flavor, offering 50% higher concentration of Vitamin B and Lysiene for appetite stimulation. The upgraded Polybion Injection also aids in faster recovery, strengthening immunity, and overcoming Vitamin B deficiency, addressing key needs of doctors and patients.

The company reported growing its market share in key categories such as Nerve Care, Vitamin E, and Nasal Decongestant. P&G Health is a market leader in the Vitamin E category with its Evion brand, achieving record share growth in the last fiscal year. Both Neurobion and Evion recorded their highest-ever unaided brand awareness this year, indicating strong consumer recall and brand equity, and reinforcing the company's position in the health and wellness sector.